Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Completion of Enrollment in METEORIC-HF, The Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure With Reduced Ejection Fraction
June 15, 2021 07:30 ET | Cytokinetics, Incorporated
Top Line Results of METEORIC-HF Expected in Early 2022 Company Plans to Submit NDA in 2H 2021 Based on Positive Results of GALACTIC-HF SOUTH SAN FRANCISCO, Calif., June 15, 2021 (GLOBE...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics to Participate in Upcoming Investor Conferences
June 02, 2021 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2021 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 31, 2021 it granted stock options to purchase an aggregate of...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics and The ALS Association Renew Partnership to Advance the Fight Against ALS
May 19, 2021 07:30 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif. and WASHINGTON, May 19, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today announced the continuation of their partnership...
Cytokinetics Announces Secondary Analysis of GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the American College of Cardiology 70th Annual Scientific Session and Published in the Journal of American College of Cardiology
May 17, 2021 08:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data from a secondary analysis of GALACTIC-HF (Global Approach to...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Presentations Related to Health Economics and Outcomes Research in Heart Failure and Hypertrophic Cardiomyopathy at American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21)
May 16, 2021 08:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 16, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new findings from analyses of claims data and electronic health records...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Three Upcoming Presentations Related to Heart Failure and Hypertrophic Cardiomyopathy at American College of Cardiology 70th Annual Scientific Session
May 10, 2021 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced three presentations at the American College of Cardiology 70th Annual...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Reports First Quarter 2021 Financial Results
May 06, 2021 16:00 ET | Cytokinetics, Incorporated
Secondary Analysis from GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session at ACC.21 Company Plans to Submit NDA for Omecamtiv Mecarbil following Recent Meeting with FDA Results...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing REDWOOD-HCM
May 06, 2021 07:30 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first site has been activated to enroll patients in REDWOOD-HCM OLE,...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics to Hold Annual Meeting of Stockholders
May 05, 2021 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 12,...